Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Completed · Phase 3

Conditions studied: Cardio-pulmonary Bypass, Coronary Artery Bypass Graft

In brief

During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.

Key facts

Study ID

NCT00048308

Run by

Alexion Pharmaceuticals, Inc.

People needed

3000

Starts

2002-01-01

Last updated by the study team

2017-02-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump. In addition, they must meet all of the following criteria:
• be at least 18 years of age;
• have one or more of the following risk factors:
• diabetes mellitus;
• prior CABG;
• the need for urgent intervention, defined according to the American College of Cardiology/ American Heart Association (ACC/AHA) guidelines as being patients who are required to stay in the hospital, but may be scheduled and operated on within a normal scheduling routine, excluding patients who have had a MI within 48 hours of CABG;
• female;
• history of a neurologic event (cerebrovascular accident, transient ischemic attack or carotid endarterectomy);
• history of congestive heart failure (New York Heart Association [NYHA]Class III or IV);
• history of 2 myocardial infarctions, or a myocardial infarction that occurred greater than 48 hours but less than four (4) weeks prior to CABG;
• provide Informed Consent.

You may not qualify if…

• A patient will be ineligible for study entry if he/she meets any of the following exclusion criteria:
• has planned aortic dissection repair and/or requires aortic root reconstruction;
• requires salvage intervention as defined by the ACC/AHA guidelines as being ongoing cardiopulmonary resuscitation on the way to the operating room;
• has current cardiogenic shock, acute left ventricular rupture, acute septal rupture or acute papillary muscle rupture;
• has uncontrolled diabetes, defined as a documented plasma blood glucose value > 400 mg/dl (22.2 mmol/L) within three (3) days before surgery;
• has a history of renal failure and a serum creatinine value greater than 3.0 mg/dl;
• has a history of chronic hepatic failure and/or hepatic cirrhosis;
• has a history of malignancy, excepting basal cell carcinoma and malignancies in remission (greater than 2 years);
• has any active bacterial or other infection which is clinically significant, in the opinion of the investigator (e.g. evaluate the evidence based on WBC, temperature, cultures, etc. as appropriate for the patient);
• has any serious medical condition which, in the opinion of the investigator is likely to alter the patient's course of recovery or the evaluation of the study medication's safety;
• has a history of alcohol or drug abuse within the past year;
• has a known or suspected hereditary complement deficiency;
• has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization;
• is receiving, or is planning to receive, any other investigational drug or device, or will participate in any other research study during the trial;
• is pregnant or breast-feeding.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• IMC-Diagnostic and Medical Clinic — Mobile, Alabama, United States
• Desert Samaritan - Lutheran Heart — Mesa, Arizona, United States
• Good Samaritan Regional Medical Center — Phoenix, Arizona, United States
• Saguaro Clinical Research — Tucson, Arizona, United States
• Southern Arizona VAMC — Tucson, Arizona, United States
• University of Arizona — Tucson, Arizona, United States
• Sparks Regional Medical Center — Fort Smith, Arkansas, United States
• University of Arkansas — Little Rock, Arkansas, United States
• Brotman Medical Center — Beverly Hills, California, United States
• Cardiovascular Associates of the Peninsula — Burlingame, California, United States
• Seton Medical Center — Daly City, California, United States
• St. Jude Medical Center — Fullerton, California, United States
• Apex Cardiology — Inglewood, California, United States
• Huntington Memorial Hospital — Los Angeles, California, United States
• University of Southern California — Los Angeles, California, United States
• St. Vincent's Hospital — Los Angeles, California, United States
• University of California - Los Angeles — Los Angeles, California, United States
• Crozer-Chester Medical Center — Oakland, California, United States
• Tri-City Medical Center — Oceanside, California, United States
• Mercy General Hospital — Sacramento, California, United States
• San Diego Cardiac Center — San Diego, California, United States
• Kaiser Foundation Hospital — San Francisco, California, United States
• UCSF Moffitt-Long Hospital — San Francisco, California, United States
• Baptist Medical Center Cardiology — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.